Methods of treating spinal cord injury and minimizing scarring

• US 20090136457A1
• Filed: 11/27/2007
• Published: 05/28/2009
• Est. Priority Date: 06/14/2006
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Sing, George L., Marshall, Vivienne S., Clarke, Diana L.
• Granted Patent: US 8,475,788 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/48 Reproductive organs
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.

Claims

1. A method for treating spinal cord injury in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions comprising ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom.

6. The method of claim 1, 2, 3, 4 or 5 wherein the ECS cells are AMP cells.

7. The method of claim 6, wherein the AMP cells are pooled AMP cells.

8. The method of claim 1, 2, 3, 4 or 5 wherein the conditioned media is ACCS.

9. The method of claim 8, wherein the ACCS is pooled ACCS.

10. The method according to claim 1, 2, 3, 4 or 5 wherein the spinal cord injury is complete spinal cord injury or incomplete spinal cord injury.

11. The method of claim 1, 2, 3, 4 or 5 wherein the ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom are administered in combination with other agents and/or treatment modalities.

2. A method for promoting the healing of a spinal cord injury in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions comprising ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom.

3. A method for stimulating growth or regeneration of spinal cord cells following spinal cord injury in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions comprising ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom, wherein the spinal cord cells are neurons, oligodendrocytes, astrocytes, microglial cells, ependymal cells, or Schwann cells.

4. A method for preventing or ameliorating scarring following spinal cord injury in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions comprising ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom.

5. A method for neuroprotecting spinal cord neurons following spinal cord injury in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions comprising ECS cells, conditioned media derived therefrom, cell lysate derived therefrom or cell products derived therefrom.